Composition: 1 ml of a sterile solution contains 0.1 ± 0.01 mg of CaCl2 and 10⁻¹⁰-10⁻¹¹ mg of a protein-peptide complex isolated from the aortic tissue of young gobies.
The physiological effect of viorgon-35 is associated with its ability to maintain the spatially functional organization of vascular endothelial cells, as well as adhesive interactions between them.
Indications for use: Viorgon-35 is recommended for use in violation of the cardiovascular system, with high (unstable blood pressure), in the rehabilitation period after myocardial infarction and ischemic strokes. with infectious diseases.
Mode of application
Viorgon can be taken by application to the mucous membrane, intranasally: by instilling into the nasal cavity, or sublingually: by ordering under the tongue. In this case, the dosage starts from 3 drops.
Viorgon can be taken orally, diluting in water at the rate of at least 8-10 drops per 100 ml of water. Drink at least 20-30 minutes before eating or 2 hours after.
A positive effect is observed from the use of 3 or more times a day. An overdose of viorgon preparations is excluded, it is allowed to take as many times a day as they will favorably affect the well-being. The addictive effect is also absent.
The interval between the various viorgons is at least 10 minutes.